Gene Expression Profiling in Clinically Localized Prostate Cancer: A Four-Gene Expression Model Predicts Clinical Behavior

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5477-5485

  Latil, Alain ^a,g   Bièche, Ivan ^b,c   Chêne, Laurent ^a   Laurendeau, Ingrid ^b   Berthon, Philippe ^a   Cussenot, Olivier ^d,e,f   Vidaud, Michel ^b  

^a Parc Scientifique de Luminy   (France)

^b ECOLE NORMALE SUPÉRIEURE   (France)

^c CENTRE RENÉ HUGUENIN   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSTITUT UNIVERSITAIRE DE FRANCE   (France)

^f Laboratoire d'Excellence Inflamex   (France)

^g UroGene   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MOLECULAR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BCL G GENE; CANCER LOCALIZATION; CANCER RECURRENCE; CARCINOGENESIS; CGA GENE; CLINICAL ARTICLE; F2R GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYVE1 GENE; MALE; PAR1 GENE; PRIORITY JOURNAL; PROSTATE CANCER; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CLASSIFICATION; XLKD1 GENE;

AGED; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; MODELS, GENETIC; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 0344629844     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997. CA Cancer J. Clin., 47: 5-27, 1997.
2. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., and Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer. Nature (Lond.), 412: 822-826, 2001.
3. Luo, J. H., Yu, Y. P., Cieply, K., Lin, F., Deflavia, P., Dhir, R., Finkelstein, S., Michalopoulos, G., and Becich, M. Gene expression analysis of prostate cancers. Mol. Carcinog., 33: 25-35, 2002.
4. Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., Lander, E. S., Loda, M., Kantoff, P. W., Golub, T. R., and Sellers, W. R. Gene expression correlates of clinical prostate cancer behavior. Cancer Cells, 1: 203-209, 2002.
5. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
6. Latil, A., Bieche, I., Vidaud, D., Lidereau, R., Berthon, P., Cussenot, O., and Vidaud, M. Evaluation of androgen, estrogen (ER α and ER β), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res., 61: 1919-1926, 2001.
7. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. Basic Local Alignment Search Tool. J. Mol. Biol., 215: 403-410, 1990.
8. Hanley, J. A., and McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 143: 29-36, 1982.
9. Didier, G., Brezellec, P., Remy, E., and Henaut, A. GeneANOVA - gene expression analysis of variance. Bioinformatics, 18: 490-491, 2002.
10. Bussemakers, M. J., van Bokhoven, A., Verhaegh, G. W., Smit, F. P., Karthaus, H. F., Schalken, J. A., Debruyne, F. M., Ru, N., and Isaacs, W. B. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res., 59: 5975-5979, 1999.
11. de Kok, J. B., Verhaegh, G. W., Roelofs, R. W., Hessels, D., Kiemeney, L. A., Aalders, T. W., Swinkels, D. W., and Schalken, J. A. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res., 62: 2695-2698, 2002.
12. Markwalder, R., and Reubi, J. C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res., 59: 1152-1159, 1999.
13. Pinski, J., Schally, A. V., Halmos, G., and Szepeshazi, K. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int. J. Cancer, 55: 963-967, 1993.
14. Zhang, M., Volpert, O., Shi, Y. H., and Bouck, N. Maspin is an angiogenesis inhibitor. Nat. Med., 6: 196-199, 2000.
15. Sheng, S., Carey, J., Seftor, E. A., Dias, L., Hendrix, M. J., and Sager, R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. USA, 93: 11669-11674, 1996.
16. Lein, M., Jung, K., Ortel, B., Stephan, C., Rothaug, W., Juchem, R., Johannsen, M., Deger, S., Schnorr, D., Loening, S., and Krell, H. W. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene, 21: 2089-2096, 2002.
17. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Wash. DC), 264: 436-440, 1994.
18. Lee, C. T., Capodieci, P., Osman, I., Fazzari, M., Ferrara, J., Scher, H. I., and Cordon-Cardo, C. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin. Cancer Res., 5: 977-983, 1999.
19. Bieche, I., Latil, A., Parfait, B., Vidaud, D., Laurendeau, I., Lidereau, R., Cussenot, O., and Vidaud, M. CGA gene (coding for the alpha subunit of glycoprotein hormones) overexpression in ER α-positive prostate tumors. Eur. Urol., 41: 335-341, 2002.
20. Bieche, I., Parfait, B., Nogues, C., Andrieu, C., Vidaud, D., Spyratos, F., Lidereau, R., and Vidaud, M. The CGA gene as new predictor of the response to endocrine therapy in ER α-positive postmenopausal breast cancer patients. Oncogene, 20: 6955-6959, 2001.
21. Prevo, R., Banerji, S., Ferguson, D. J., Clasper, S., and Jackson, D. G. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J. Biol. Chem., 276: 19420-19430, 2001.
22. Padera, T. P., Kadambi, A., di Tomaso, E., Carreira, C. M., Brown, E. B., Boucher, Y., Choi, N. C., Mathisen, D., Wain, J., Mark, E. J., Munn, L. L., and Jain, R. K. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (Wash. DC), 296: 1883-1886, 2002.
23. Mandriota, S. J., Jussila, L., Jeltsch, M., Compagni, A., Baetens, D., Prevo, R., Banerji, S., Huarte, J., Montesano, R., Jackson, D. G., Orci, L., Alitalo, K., Christofori, G., and Pepper, M. S. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J., 20: 672-682, 2001.
24. Huang, Y. Q., Li, J. J., Hu, L., Lee, M., and Karpatkin, S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb. Haemost., 86: 1094-1098, 2001.
25. Guo, B., Godzik, A., and Reed, J. C. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J. Biol. Chem., 276: 2780-2785, 2001.